75 related articles for article (PubMed ID: 15523142)
21. Recurrent femur neck fracture and response to bisphosphonates in polyostotic fibrous dysplasia.
Rastogi A; Bhadada SK; Bhansali A
Indian J Pediatr; 2012 May; 79(5):667-9. PubMed ID: 21761121
[TBL] [Abstract][Full Text] [Related]
22. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
[TBL] [Abstract][Full Text] [Related]
23. Alendronate and pharmacological doses of 1alpha OHD3 therapy in a patient with McCune-Albright syndrome and accompanying hypophosphatemia.
Yamamoto T; Ozono K; Shima M; Yoshikawa H; Okada S
J Bone Miner Metab; 2002; 20(3):170-3. PubMed ID: 11984700
[No Abstract] [Full Text] [Related]
24. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
[No Abstract] [Full Text] [Related]
25. Oral mucosal irritation with incorrect use of alendronate.
Aleid W; Sidebottom A
Br J Oral Maxillofac Surg; 2009 Mar; 47(2):170-1. PubMed ID: 18814944
[No Abstract] [Full Text] [Related]
26. Intragastric alendronate therapy in two infants with vitamin D intoxication: a new method.
Doneray H; Ozkan B; Caner I; Ozkan A; Karakelleoglu C
Clin Toxicol (Phila); 2008 Apr; 46(4):300-2. PubMed ID: 18363123
[TBL] [Abstract][Full Text] [Related]
27. Drug injury in the upper gastrointestinal tract: effects of alendronate.
Khapra AP; Rose S
Gastrointest Endosc Clin N Am; 2006 Jan; 16(1):99-110. PubMed ID: 16546026
[TBL] [Abstract][Full Text] [Related]
28. The prognosis for dental implants placed in patients taking oral bisphosphonates.
Kasai T; Pogrel MA; Hossaini M
J Calif Dent Assoc; 2009 Jan; 37(1):39-42. PubMed ID: 19263627
[TBL] [Abstract][Full Text] [Related]
29. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
30. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
[TBL] [Abstract][Full Text] [Related]
31. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
32. An extensive hemimelic polyostotic fibrous dysplasia: a case report.
Mrabet D; Rekik S; Sahli H; Ben Amor M; Meddeb N; Sellami S
Rheumatol Int; 2012 Apr; 32(4):1075-8. PubMed ID: 21331571
[TBL] [Abstract][Full Text] [Related]
33. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
[TBL] [Abstract][Full Text] [Related]
34. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
[TBL] [Abstract][Full Text] [Related]
35. Use of alendronate in the treatment of vitamin D intoxication in infants.
Hatun S; Cizmecioğlu F
Turk J Pediatr; 2005; 47(4):373-5. PubMed ID: 16363349
[TBL] [Abstract][Full Text] [Related]
36. [Cost effective osteoporosis therapy. Alendronate is also immediately available as a generic drug].
MMW Fortschr Med; 2005 Dec; 147(49-50):74-5. PubMed ID: 16401016
[No Abstract] [Full Text] [Related]
37. Efficacy of alendronate in the treatment of the SAPHO syndrome.
Fioravanti A; Cantarini L; Burroni L; Mazzei MA; Volterrani L; Galeazzi M
J Clin Rheumatol; 2008 Jun; 14(3):183-4. PubMed ID: 18525442
[No Abstract] [Full Text] [Related]
38. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
39. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
40. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
